Antibiotic resistance is a complex issue involving many actors, such as patients, prescribers, providers, the pharmaceutical industry and politicians. In a way, all of us have contributed to the current situation, but who is responsible for taking actions to solve the problem of access vs. excess and how can it be done?
Please reflect upon the following questions:
- Who is responsible for the fair distribution of antibiotics worldwide?
- How do we find distribution models that increase access to effective antibiotics while reducing excess use in low- and middle-income countries?
© Uppsala University
More from "Part 3"
- Nearly empty pipeline
- Why don’t we simply develop new antibiotics?
- Alternatives to antibiotics
- New business models addressing antibiotic resistance
- How can we tackle this rather critical situation?
- Innovation of antibiotics
- Securing access while reducing excess
- Access not excess – rational use of antibiotics
- Who is responsible?
- Test your understanding III
- Reflection and analysis: the access-excess dilemma
- End of part 3